Salmodil

Quick links to important sections

Salmodil

Method of action: Expectorant

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salmodil

Property Description
Active Ingredients Salbutamol and Bromhexine
Form Oral Syrup and Tablet
Pharmacological Class Combination Bronchodilator and Mucolytic Agent
Common Use Relief from chesty cough and difficulty breathing
Origin Synthetic

What Type of Medicine is Salmodil?

Salmodil is a synthetic combination product taken via the oral route that contains two different active ingredients, establishing its classification as a combined Bronchodilator and Mucolytic Agent. This approach is formulated to address concurrent issues of restricted airflow and the presence of excessive, viscous secretions. Its dual mechanism contrasts with single-agent therapies by providing integrated symptomatic relief. The combination of these agents is designed for the simultaneous treatment of bronchospasm and mucus production.

Composition and the Dual-Action Principle

The product relies on the two key synthetic components: Salbutamol (also known as Albuterol), a beta2-adrenergic agonist which acts to promote the relaxation of bronchial smooth muscle, and Bromhexine, which serves as the mucolytic agent. Salbutamol is included for addressing narrowed air passages, while Bromhexine facilitates the breakdown of thick, difficult-to-clear mucus. This combination is intended to address the symptoms of a wet, congested cough.

General Purpose: Relief from Airway and Mucus Congestion

The general purpose of Salmodil is to ease breathing by alleviating the distress caused by the concurrent restriction of airflow (bronchospasm) and the presence of tenacious, excessive mucus (phlegm). For instance, it is typically used in a scenario where a patient experiences a cough that feels deep and stuck in the chest. The combined action of widening the airways and thinning the secretions is intended to make a productive, chesty cough more effective. This leads to the outcome of improving airway patency and facilitating the expulsion of secretions from the respiratory tract.

What side effects are possible with Salmodil?

Possible Side Effects and Safety Information

The officially documented safety profile for Salmodil (Salbutamol/Bromhexine) is structured around the known adverse reactions of its two components, categorized by frequency and the body system affected, according to regulatory standards.

Adverse Reaction Classification

Side effects related to the sympathomimetic component, Salbutamol, are generally dose-related. Common adverse reactions are often more pronounced at the initiation of treatment and include fine tremor (shakiness), headache, palpitations, and tachycardia (increased heart rate). Less common effects include muscle cramps and gastrointestinal disturbances like nausea and vomiting, the latter often associated with Bromhexine.

Frequency Classification Examples of Documented Effects
Common Tremor, Headache, Palpitations, Tachycardia
Rare Hypokalaemia (low potassium levels), Peripheral vasodilatation, Hypersensitivity reactions

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for Serious Adverse Reactions (SARs). These include severe hypersensitivity reactions (such as anaphylaxis) and, rarely, paradoxical bronchospasm—an acute, unexpected worsening of breathing difficulties. Additionally, Bromhexine-containing products have been associated with reports of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety constraints require caution in specific patient populations. Due to Salbutamol’s effects, caution is advised for individuals with pre-existing severe cardiovascular disorders (e.g., certain arrhythmias or ischemic heart disease) or diabetes mellitus. Furthermore, reduced clearance of the Bromhexine component may occur in patients with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes that overdose symptoms are primarily due to the Salbutamol component, reflecting excessive beta-agonist activity. Manifestations may include tachycardia (fast heart rate), tremor, palpitations, and headache. Severe physiological findings include hypokalemia (low serum potassium), hyperglycemia (high blood glucose), and lactic acidosis.

Overdose has been associated with severe and potentially fatal outcomes, including cardiac arrest and cardiac arrhythmias. Regulatory labels mandate that individuals must seek immediate medical attention or call emergency services if an overdose is suspected or if symptoms such as severe chest pain or an irregular heartbeat occur.

Management is defined as symptomatic and supportive treatment. Official guidance requires monitoring of serum potassium and lactate levels to address known metabolic disturbances. It is noted that no specific antidote is known for overdose of the Bromhexine component. Overdose in the oral formulation has reported nausea, vomiting, and hyperglycemia predominantly in children.

Therapeutic Uses of Salmodil

This medicine is commonly used to provide symptomatic relief in clinical situations where patients experience the concurrent combination of restricted airflow (bronchospasm) and a heavy, mucus-filled cough. It is relevant in conditions characterized by periods of heightened symptoms, such as Bronchial Asthma, Chronic Bronchitis (a component of COPD), and Whooping Cough, which present with episodic or acute manifestations. The medication helps address symptom clusters that interfere with daily comfort during difficult episodes.

This therapeutic scope is aimed at easing symptoms related to heightened physiological activity, such as difficulty breathing, wheezing, and chest tightness arising from airway restriction. It is also applied in scenarios where symptoms create noticeable functional strain due to thick, tenacious phlegm making the cough less effective and leading to persistent respiratory congestion.

The main patient benefit is supportive: The combination contributes to easing the overall symptom load and helps improve day-to-day comfort during periods of heightened symptoms.

Quick Fact: Symptomatic Support Summary
This combination is relevant in clinical settings that involve acute or unstable symptom patterns and is applied when additional symptomatic support is needed to address both airway constriction and tenacious mucus.

Eligibility and Restrictions for Use

Eligibility Profile for Salmodil (Salbutamol + Bromhexine)

Official regulatory documents define specific populations who can and cannot use Salmodil, primarily based on contraindications linked to its active components.

Absolute Contraindications

The medicine must not be used by patients with a known hypersensitivity or allergy to Salbutamol or Bromhexine. Use is also prohibited for individuals with certain severe, pre-existing conditions, including Angina Pectoris, severe cardiovascular diseases (like cardiac dysrhythmias), and Hyperthyroidism (Thyrotoxicosis).

Age and Condition Restrictions

Established Use is defined for adults and adolescents (over 12 years), and children 6 to 12 years with specific guidance. Children under 2 years are a group where safety and effectiveness are not adequately demonstrated.

Caution is required in populations with Severe Hepatic Impairment or Severe Renal Impairment, as well as those with Diabetes Mellitus or a history of gastric or peptic ulceration. Additionally, use during pregnancy and lactation is generally not recommended, and is conditional upon strict medical assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction patterns for Salmodil (Salbutamol and Bromhexine) as described in government regulatory documents.


Documented Drug-Drug Interactions

Contraindicated Combinations and Restrictions

Co-administration with non-selective Beta-adrenergic Blocking Agents (e.g., Propranolol) is generally restricted as these substances can block the bronchodilatory effect of Salbutamol and may induce severe bronchospasm. The Bromhexine component carries a restriction against co-administration with Antitussives (cough suppressants) because this combination can hamper the effective expulsion of diluted sputum. Use with Other Oral Sympathomimetic Agents is also not recommended due to the potential for deleterious cardiovascular effects.

Pharmacodynamic and Exposure Effects

Substances such as Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the effect of Salbutamol on the vascular system. Co-administration with Diuretics or Corticosteroids may augment the hypokalemic effect associated with Salbutamol. Digoxin plasma levels may be decreased when co-administered with Salbutamol. Bromhexine is documented to promote the concentration and penetration of certain Antibiotics (e.g., Amoxycillin, Erythromycin) into the pulmonary tissue.


Population-Dependent Interaction Notes

The official labeling notes that in cases of severe hepatic or renal impairment, the systemic clearance of Bromhexine or its metabolites may be reduced, which can alter systemic exposure.

Mechanism of Action

How Salmodil Works: Mechanistic Domains

beta2-Adrenergic Receptor Agonism

This core mechanistic domain involves the binding of the beta2-agonist component to specific G-protein coupled receptors located on airway smooth muscle cells. This receptor-mediated signaling triggers the activation of adenylyl cyclase, which increases the intracellular concentration of cyclic AMP (cAMP). The resultant elevation in cAMP initiates a cascade that leads to the inactivation of myosin light-chain kinase and a decrease in intracellular calcium (Ca^2+) levels. The final cellular consequence is the reduction of contractile tension within the smooth muscle fibers, thus modulating signal propagation in the airway by decreasing downstream adrenoreceptor-mediated excitability.


Mucolytic and Expectorant Pathway Modulation

This auxiliary domain engages mechanisms that directly influence the rheological properties of respiratory tract secretions. The mucolytic agent acts within systems to break down complex mucoproteins and potentially increase pulmonary surfactant production, thereby modifying the viscoelastic properties of mucus. Concurrently, the expectorant component supports the regulation of secretory processes by increasing the volume of airway fluid and reducing the adhesiveness of mucus. This combined action induces a net enhancement of ciliary transportability through modification of secretion volume and consistency.

Dosage and Administration Information

How to Use Salmodil: Official Administration Guidelines

The usage protocol for the Salbutamol and Bromhexine oral combination product encompasses the appropriate route, volumetric dose, and frequency of administration. This medicine is administered via the oral route as a syrup or liquid solution. The regimen is designed for standardized use during periods of symptom presentation.


Official Dosing and Frequency

The required dosing frequency is generally three to four times daily. This schedule establishes the pattern for consistent delivery of the active ingredients throughout the day, providing short-acting support.

Age Group Typical Single Dose Range (Syrup)
Adults 10 ml to 20 ml
Children (6-12 years) 5 ml to 10 ml
Children (2-6 years) 2.5 ml to 5 ml

The maximum adult daily dose should not be exceeded. Administration may be done with or without food. For children under 6 years, administration is subject to specific professional guidance as defined in the product labeling.


Preparation and Procedural Requirements

For proper administration, the liquid formulation must be shaken well before use to ensure a uniform mixture of the active components. The correct volume must be measured precisely using a calibrated measuring device provided for the medicine. If a scheduled dose is missed, the standard approach is to take the next dose at the regular time, rather than doubling the subsequent dose.


Recent Clinical Evidence

Research Evidence / Overview of Studies for Salmodil

This section summarizes the type of research that has examined the combination of Salbutamol and Bromhexine (Salmodil). It focuses on the scope of the studies, what they measured, and areas where evidence is still emerging or limited, strictly without offering medical advice or making claims about personal outcomes.


Evidence for Use in Chronic Obstructive Airway Conditions

Research related to this combination was evaluated in conditions characterized by both restricted airflow (bronchospasm) and the presence of thick mucus, such as Chronic Bronchitis (a component of COPD). Studies explored this combination in the context of conditions characterized by fluctuating or episodic manifestations.

The research examined objective lung function metrics, such as how much air patients could forcefully exhale in one second, as well as patient-reported outcomes describing perceived discomfort, like difficulty breathing and cough severity. However, foundational evidence, such as large-scale systematic reviews and meta-analyses, often describes the individual components (Salbutamol or Bromhexine) or on combinations involving different drugs. Evidence for this specific dual product is more limited and often relies on smaller, regional trials or open-label studies.


Evidence for Symptom Relief from Mucus-Filled Cough and Bronchospasm

The combination was studied in trials that focused on symptom outcomes of acute episodes where patients present with a heavy, productive cough associated with airway constriction. Research exploring short-term symptom changes focused on studies conducted during periods of increased symptom activity.

These trials assessing short-term or episodic symptom patterns by monitoring subjective changes. Researchers documented data show patterns related to how symptom intensity evolved in the observed populations, particularly noting changes in the Cough Severity Score. Studies also examined physical outcomes, such as how the consistency and volume of secretions changed during the study period. This evidence contributes to the broader evidence landscape by providing context on short-term changes measured by the studies.


What the Research Indicates is Still Uncertain

The clinical research highlights what is known—and what is still uncertain—about Salmodil. A primary research limitation is that comparative evidence is lacking between the specific Salbutamol and Bromhexine combination and other commonly prescribed dual or triple respiratory combination therapies on a global scale.

The available evidence includes studies that vary in design and size because many foundational reviews examine the components individually or in combination with other active agents, rather than isolating the effect of this fixed-dose product alone. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Albuterol and Mucolytic Combination Product Information

Frequently Asked Questions (FAQ)

Common questions about Salmodil (FAQ)


Q: What is the main difference between Salmodil and other similar medicines?

Official documents describe Salmodil as a fixed-dose combination product containing a bronchodilator (Salbutamol) and a mucolytic agent (Bromhexine).

The product is formulated to address both restricted airflow and the presence of excessive, viscous secretions concurrently.


Q: What health issues is Salmodil officially approved to treat?

According to official regulatory documents, this medicine is indicated for relieving cough in several bronchopulmonary disorders.

These typically include conditions like chronic bronchitis, bronchial asthma, and emphysema, especially when both airway constriction and difficulties expelling mucus are present.


Q: Why do people sometimes call Salmodil a 'rescue' medication?

The term is sometimes used because the Salbutamol component is a short-acting beta2-agonist, which is designed to work quickly to help relax the smooth muscles of the airways.

This class of medicine is intended to provide rapid symptomatic relief during acute episodes of restricted breathing.


Q: How long does the effect of Salmodil typically last?

The bronchodilator component, Salbutamol, is classified as a short-acting agent.

Official information indicates that the bronchodilating effect typically lasts approximately four to six hours in most patients.


Q: Is Salmodil considered a long-term or short-term treatment?

This medicine is generally described as intended for short-term, symptomatic relief.

Official warnings note that increasing use or reliance on the short-acting component is considered a sign that the underlying condition may be worsening, which indicates the need for professional re-assessment.


Q: What happens if Salmodil is used for too long?

Official warnings note that an increase in reliance on the bronchodilator component, or a decrease in its usual effectiveness, is an important signal of potential disease deterioration.

In this situation, the product labeling advises that the patient’s overall treatment plan should be reassessed. Known effects associated with overdose include tremor and a fast heart rate.


Q: Does Salmodil affect sleep patterns?

Official product information lists potential side effects from the Salbutamol component, such as nervousness, hyperactivity, or fine tremor (shakiness).

While not listed as insomnia, these effects could potentially interfere with sleep patterns for some users.


Q: Are there different forms of Salmodil available (e.g., tablet, liquid, inhaler)?

This specific combination product is typically available in forms designed for oral consumption, such as a liquid solution or tablets.

Official regulatory registries confirm it is not registered as an inhaler formulation.


Q: Is Salmodil safe for older adults or elderly patients?

Regulatory documentation notes that the medicine is generally for use by adults, but older patients may exhibit increased sensitivity to its side effects.

Due to this potential for heightened sensitivity, professional guidance may advise the initiation of therapy with caution.


Q: How is Salmodil different from a preventive medicine?

Salmodil provides immediate relief from acute symptoms (like restricted airflow) via its short-acting bronchodilator component.

This contrasts with preventive or maintenance medicines, such as inhaled anti-inflammatory corticosteroids, which are used daily for long-term control of the underlying respiratory disease.


Q: How long can I expect to wait before needing the next use of Salmodil?

Official information states that the medicine is typically administered based on a frequency designed to maintain consistent short-acting support.

The duration of effect of the bronchodilator component is generally noted to be approximately four to six hours, which establishes the expected pattern for use.


Q: Is there a generic version of Salmodil available?

Official drug registries show that the combination of Salbutamol and Bromhexine is available under various generic names and multiple brand names globally.

The specific product names available will vary depending on the country of regulation.


Q: Why does Salmodil need to be prescribed by a doctor?

This medicine is classified as a prescription-only drug (Rx) by regulatory authorities.

This requirement is due to the potential for serious adverse effects associated with the bronchodilator component, such as hypokalemia (low potassium levels) and cardiovascular effects, which necessitate clinical supervision.


Q: Does the effectiveness of Salmodil decrease over time?

Regulatory documents state that if a decrease in the usual relief or duration of effect is observed, this is considered a warning sign.

Such a change indicates potential deterioration of the underlying condition, which warrants a professional review of the patient's treatment plan.


Q: Are there any activities I should avoid while using Salmodil?

Official product information includes warnings regarding potential impairment.

Patients are cautioned about undertaking activities that require full mental alertness, such as driving or operating heavy machinery, if they experience side effects like dizziness, sleepiness, or significant shakiness.


Q: What if I experience mild side effects from Salmodil?

The medicine's safety information lists common side effects like headache or fine tremor, which are generally described as mild and transient.

Regulatory guidance emphasizes that any side effect, particularly if it becomes severe, unusual, or persistent, should be discussed with a healthcare provider.


Q: Can Salmodil be used for exercise-induced breathing issues?

While the Salbutamol component alone is often indicated for the prevention of exercise-induced bronchospasm, this specific combination product is generally indicated for respiratory conditions where both airflow restriction and excess mucus are present.


Q: Does Salmodil interact with caffeine or other stimulants?

Official documents note a restriction against the concomitant use of this product with other oral sympathomimetic agents (a class of stimulants) due to the potential for increased cardiovascular effects.

Caution may be necessary when consuming dietary stimulants like caffeine, which can have similar effects.


Q: What does the research say about Salmodil's effectiveness in different age groups?

Official documents define different regimens for use in adults, adolescents, and children above two years of age.

Regulatory information also specifies that the safety and effectiveness of this combination product have not been adequately established in children under two years of age.


Q: What is the difference between Salmodil and a maintenance treatment?

Salmodil provides short-acting relief by opening the airways and thinning mucus, addressing immediate symptoms.

Maintenance treatments, conversely, are typically anti-inflammatory medications taken daily to manage and control the underlying disease progression over the long term.


Q: Is it normal to feel dry mouth after using Salmodil?

Yes, official product information lists dry mouth as one of the possible undesirable effects reported in association with the use of the medicine.


Q: Are there any specific patient monitoring requirements while using Salmodil?

Official safety warnings advise caution for patients who may be susceptible to hypokalemia (low potassium levels).

In certain clinical situations, such as acute severe asthma, regulatory documents indicate that monitoring of serum potassium levels may be a necessary precaution.


Q: Does alcohol consumption affect how Salmodil works?

Official regulatory documents include a warning that alcohol consumption may potentially worsen some side effects of the medicine, such as sleepiness or dizziness.

Patients are advised to limit alcohol intake while using this product.


Q: What is the standard duration of therapy described for Salmodil?

The product is used for symptomatic relief. Regulatory guidance concerning the mucolytic component often describes the intended duration of treatment as short-term, typically not exceeding eight to ten days, unless a specialized longer course is professionally determined.


Q: Is Salmodil used for conditions other than respiratory issues?

The official therapeutic indications, as described in regulatory documents, are exclusively focused on the treatment of bronchopulmonary disorders and the associated symptoms of cough and bronchospasm.

How should Salmodil be stored and disposed of?

How to Store and Dispose of Salmodil?

Salmodil (Salbutamol and Bromhexine) must be stored and handled according to the instructions on its official regulatory label to maintain product stability.

Item Official Storage Requirement
Temperature Store at a controlled room temperature, typically below 30 C.
Environmental Protection Protect from direct sunlight and excessive moisture; the syrup formulation must not be frozen.
Packaging Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety Mandatory requirement to keep out of the sight and reach of children.
Disposal Dispose of unused or expired medicine according to local regulatory requirements; it must not be thrown into wastewater.

These requirements define that storage must prioritize temperature control and environmental protection. Disposal must follow regulatory guidance and avoid contaminating sewage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Salmodil found in:

A-Z Index: